$RVMD News

Bernstein Maintains Market Perform on Revolution Medicines, Raises Price Target to $179

Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $231

Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years

High Risk, High Reward: Inside The Revolution Medicines Bull Case

RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $203

Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $201

Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $230

Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $240

Needham Maintains Buy on Revolution Medicines, Raises Price Target to $240

Revolution Medicines (NASDAQ:RVMD) Misses Q2 Estimates, Yet FDA Accepts Daraxonrasib Application

Revolution Medicines Q2 EPS $(3.06) Misses $(1.98) Estimate

Revolution Medicines (NASDAQ:RVMD) Flashes Strong Technical Breakout Setup

Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $192.1

Revolution Medicines' New Drug Application For Daraxonrasib Receives FDA Acceptance For Review To Treat Metastatic Pancreatic Ductal Adenocarcinoma

Needham Maintains Buy on Revolution Medicines, Raises Price Target to $236

Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $235

European Medicines Agency's Human Medicines Committee Initiates Phased Review Of Revolution Medicines' Daraxonrasib To Treat Metastatic Pancreatic Cancer

HC Wainwright & Co. Reiterates Buy on Revolution Medicines, Maintains $195 Price Target

Mizuho Maintains Outperform on Revolution Medicines, Raises Price Target to $215

Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $181